PLOS CURRENT OUTBREAKS Nov. 21, 2014 By David Fisman and Ashleigh Tuite, Dalla Lana School of Public Health, University of Toronto
As removal of population-level susceptibility through vaccination could be a highly impactful control measure for this epidemic, we sought to estimate the number of vaccine doses and timing of vaccine administration required to reduce the epidemic size. Our base model was fit using the IDEA approach, a single equation model that has been successful to date in describing Ebola growth. We projected the future course of the Ebola epidemic using this model. Vaccination was assumed to reduce the effective reproductive number. We evaluated the potential impact of vaccination on epidemic trajectory under different assumptions around timing of vaccine availability.
Scientists are scurrying to get their Ebola vaccines through the necessary safety trials before they can be used widely. That includes the University of Maryland School of Medicine, which recently kicked off the latest step in their research: figuring out the appropriate dosing for the vaccine that’s both effective and safe.
The University of Maryland is one of a handful of institutions involved in the testing of an experimental but promising vaccine developed by the National Institutes of Health’s Vaccine Research Center (VRC) and GlaxoSmithKline (GSK). The hope is that the vaccine will pass through early trials needed by end of December so that the World Health Organization (WHO) and a panel of outside experts can decide whether to move on to a large efficacy trial, which would mean vaccinating a lot of people in West Africa to see how well it works.
Manufacturers Strain to Meet Demand Amid Rising Anxiety
WALL STREET JOURNAL Nov. 25, 2014 By Drew Hinshaw in Accra, Ghana, and Jacob Bunge in Chicago
Protective suits were running low in Sierra Leone this month, when a Christian charity decided to ship some over. The charity turned to American medical-wear suppliers, which came back with bad news: The suits needed to treat Ebola are running low in America, too.
A worker wearing Personal Protective Equipment has his name written on his suit before leaving an Ebola treatment center in Guinea last week. Agence France-Presse/Getty Images
“There’s been some sleepless nights,” said Jennifer Mounsey, director of corporate engagement for World Vision, the Christian humanitarian group based in Monrovia, Calif. “We’re all sweating bullets.”
Ebola was one of the biggest news stories this year. What did we learn from it? Not much. Panic and fear replaced rational thinking. And there was another pernicious behavior we didn’t change.
Ebola would have been a chance to start differentiating Africa. Yet, we’re doing quite the opposite. We continue to look at Africa as one country. We act as if the whole continent is contaminated. And most sadly, outside Africa we stigmatize Africans, no matter which part of the continent they’re from, because of Ebola.
The U.N. Ebola Emergency Response Mission will not fully meet its Dec. 1 target for containing the virus due to escalating numbers of cases in Sierra Leone, Anthony Banbury, the head of UNMEER, said on Monday.
A health worker fixes another health worker's protective suit in the Aberdeen district of Freetown, Sierra Leone, October 14, 2014. Credit: Reuters/Josephus Olu-Mammah
The mission set the goal in September of having 70 percent of Ebola patients under treatment and 70 percent of victims safely buried. That target will be achieved in some areas, Banbury told Reuters, citing progress in Liberia.
INTERNAL DISPLACEMENT MONITORING CENTRE Nov.19, 2014
When a whole town was displaced in the south of Guinea during the Ebola crisis, the link between disease and displacement began to emerge. With IDMC monitoring the crisis across the three countries most affected since the outbreak took place, we have identified five key displacement trends emerging.
On 14 November 2014 the UN Mission for Ebola Emergency Response (UNMEER) reported that the Guinean government had announced the withdrawal of troops from Womey, Nzérékoré prefecture, in the south of the country when a group of people raising awareness about the Ebola Virus Disease (EVD) were killed by angry residents.
Since the army’s deployment in September, there have been accusations of human rights violations at the hands of military personnel, resulting in the displacement of the whole town, with some 6,000 residents fleeing to forests in the surrounding area. This is the single largest reported incident of displacement during the Ebola crisis.
NEW YORK TIMES By Anemona Hartocollis NOV. 24, 2014
NEW YORK ...since Kaci Hickox, a nurse, flew into Newark’s airport on Oct. 24 and was kept at a hospital for three days, no one else has been caught up in the quarantine dragnet at the New York and New Jersey airports.
The absence of quarantines is striking, not only because both governors emphatically defended the policy as a necessary precaution, but also because most people returning from Ebola-stricken countries arrive in the United States through Kennedy and Newark Liberty International Airports.
...New York and New Jersey officials say no one coming through the two airports since Ms. Hickox has reported direct contact with Ebola patients.
The FDA announced Friday that it would start developing a stockpile of blood plasma from Ebola survivors, treated with a pathogen inactivation system that’s never been used before in the United States.
So far, the US has had some amazing success in curing Ebola, possibly thanks to experimental plasma treatments. Drawn from survivors, the stuff comes enriched in antibodies that could help to fight off the disease—but it also has the potential to carry other diseases, like malaria, that are common in west Africa where Ebola is raging. The new system will kill off any extra contaminants that may be lurking in this potentially live-saving serum.
It’s the same one, Cerus Corporation’s Intercept system, that will be used in a Gates Foundation-funded study of Ebola treatments in West Africa. The pathogen-killing molecule at the heart of the system is amotosalen, part of a class of three-ringed molecules called psoralens....
MILAN --An Italian doctor who has been working in Sierra Leone has tested positive for the Ebola virus and is being transferred to Rome for treatment, the health ministry said Monday. It is Italy's first confirmed case of Ebola.
The doctor, who was not identified and who works for the non-governmental organization Emergency, is scheduled to arrive overnight in Italy for treatment at the Lazzaro Spallanzani National Institute for Infectious Diseases in Rome.
Emergency, which is operating a center for Ebola treatment in Lakka, Sierra Leone, said in statement that the doctor was in good condition, and that its staff in the country is following protocols aimed at avoiding contagion. "Nonetheless, no health intervention of such a serious epidemic can be considered completely without risks," Emergency said.
Recent Comments